drugset / Trial / NCT02401295

ATRA, Celecoxib, and Itraconazole as Maintenance

NCT02401295

Phase 1 Completed 1 enrolled University of Iowa
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability associated with the combination of ATRA/celecoxib/itraconazole as maintenance therapy given after an autologous stem cell transplant in relapsed multiple myeloma patients.

Timeline

Start
2015-05
Primary completion
2015-08
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg Oral
Subject Itraconazole Small molecule 200 mg Oral
Subject Tretinoin Small molecule 20 mg Oral

Indications